SEC Form 5 · accession 0001209191-19-010177
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Tilton
Officer — Chief Commercial Officer
Period of report
Dec 31, 2018
Accepted (ET)
Feb 14, 2019 · 4:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $32.42 | Nov 20, 2018 | A | 30,000 | A | — | Nov 19, 2028 | Common Shares | 30,000 | 30,000 | D |
Explanation of responses
- F1The shares underlying this option vest in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the reporting person's continuous service with the issuer at each vesting date.